Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.02.2024 | Case report

Dalbavancin/daptomycin/linezolid

Asthenia, liver and kidney injury, and treatment failure

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Ruiz-Sancho A, et al. Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety. Frontiers in Pharmacology 14: Jan 2023. Available from: URL: 10.3389/fphar.2023.1185602 Ruiz-Sancho A, et al. Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety. Frontiers in Pharmacology 14: Jan 2023. Available from: URL: 10.3389/fphar.2023.1185602
Metadaten
Titel
Dalbavancin/daptomycin/linezolid
Asthenia, liver and kidney injury, and treatment failure
Publikationsdatum
01.02.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-53328-9

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Doxycycline

Case report

Metronidazole

Case report

Multiple drugs

Case report

Ibrutinib